Remicade (infliximab): Side effects, dosage, cost, and more

What is Remicade?

Remicade is the brand name for infliximab, a biologic medication known as a tumor necrosis factor-alpha inhibitor, or TNF blocker. Biologic drugs are produced using living cells and are more structurally complex than ordinary small-molecule tablets.

TNF-alpha is a protein that helps coordinate inflammation. That is useful when the body is responding to an infection or injury. In certain autoimmune diseases, however, the immune system produces or responds to inflammatory signals too aggressively. It begins acting like an overenthusiastic security guard that tackles the furniture along with the intruder.

Infliximab binds to TNF-alpha and reduces its inflammatory activity. This can ease swelling, pain, stiffness, diarrhea, intestinal bleeding, skin plaques, and other symptoms associated with immune-mediated disease.

Conditions Remicade is approved to treat

• Moderately to severely active Crohn’s disease in adults
• Fistulizing Crohn’s disease in adults
• Moderately to severely active Crohn’s disease in children ages 6 and older
• Moderately to severely active ulcerative colitis in adults
• Moderately to severely active ulcerative colitis in children ages 6 and older
• Moderately to severely active rheumatoid arthritis in adults, in combination with methotrexate
• Active ankylosing spondylitis in adults
• Active psoriatic arthritis in adults
• Chronic severe plaque psoriasis in appropriate adult candidates for systemic treatment

Infliximab may occasionally be prescribed for other conditions. Such use is considered off-label and should be guided by a specialist who has weighed the evidence, alternatives, and individual risks.

How Remicade is given

Remicade does not arrive as a cheerful little pill in a weekly organizer. It books a chair.

A trained healthcare professional administers the medication through an IV line in a medical office, hospital outpatient department, infusion center, or another appropriately monitored setting. The dose is calculated according to body weight and the condition being treated.

The infusion is generally administered over at least two hours. Staff monitor the patient during treatment because allergic, cardiovascular, or other infusion-related reactions can occur. Depending on the patient’s history and the clinic’s protocol, acetaminophen, an antihistamine, or a corticosteroid may be given before the infusion to reduce the risk or severity of a reaction.

Blood pressure, temperature, pulse, and breathing may be checked before, during, and after treatment. Some patients remain under observation for a period after the infusion, particularly during early doses or after a previous reaction.

Remicade dosage and infusion schedule

The correct Remicade dosage depends on the diagnosis, body weight, treatment response, side effects, other medications, and sometimes laboratory findings. Patients should never attempt to change an infusion dose or interval on their own.

The first three doses are commonly called the induction phase. They are scheduled relatively close together to establish disease control. Later doses form the maintenance phase.

Higher or more frequent doses can increase infection risk and are not suitable for every patient. Doses above 5 mg/kg are contraindicated in people with moderate or severe heart failure. Any escalation requires a careful benefit-risk discussion.

What happens if an infusion is missed?

Contact the prescribing office or infusion center as soon as possible. Do not wait until the next scheduled date without discussing it. A long interruption may allow symptoms to return, increase the likelihood of anti-drug antibodies, and make a future infusion reaction more likely.

There is no “double infusion” solution. Remicade is not laundry detergent, and more is definitely not automatically better.

How quickly does Remicade work?

Some patients notice improvement after the first or second dose. For others, meaningful improvement takes several infusions, and the full benefit may require three to six months.

The timeline varies with the disease being treated. A person with inflammatory bowel disease may first notice fewer bowel movements, less bleeding, or improved appetite. Someone with inflammatory arthritis may notice less morning stiffness, reduced swelling, or improved mobility.

Feeling better does not always mean inflammation is fully controlled. Clinicians may use blood tests, stool markers, imaging, physical examinations, endoscopy, skin assessments, or disease-activity questionnaires to measure response more objectively.

If Crohn’s disease has not improved adequately by the expected evaluation point, or if another condition remains active despite appropriate treatment, the clinician may adjust the regimen or recommend a different therapy.

Common Remicade side effects

The most frequently reported side effects include:

• Upper respiratory infections
• Sinus infections
• Sore throat
• Headache
• Abdominal pain
• Cough
• Nausea or heartburn
• Runny or stuffy nose
• Flushing
• Mild rash or itching
• Infusion-related symptoms

These effects are not automatically dangerous, but persistent, worsening, or unusual symptoms should be reported. Because infliximab changes immune activity, what initially looks like “just a cold” deserves more attention than it might otherwise receive.

Immediate infusion reactions

An immediate reaction can develop during an infusion or shortly afterward. Possible symptoms include:

• Fever or chills
• Itching, hives, or rash
• Flushing
• Headache
• Dizziness or fainting
• Chest pain
• Changes in blood pressure
• Shortness of breath or wheezing
• Swelling of the face, tongue, lips, or throat
• Difficulty swallowing

Patients should tell the infusion nurse immediately, even if a symptom seems minor. The team may slow or stop the infusion and provide medication. Severe reactions require emergency treatment and may mean Remicade should be discontinued.

Delayed reactions

A delayed hypersensitivity or serum sickness-like reaction may appear several days after treatment, particularly when infliximab is restarted after a long interruption. Symptoms can include fever, rash, headache, sore throat, muscle pain, joint pain, facial or hand swelling, itching, and difficulty swallowing.

These symptoms should be reported promptly rather than saved for the next routine appointment.

Serious Remicade risks and boxed warnings

Remicade carries an FDA boxed warning for serious infections and malignancy. A boxed warning is the agency’s strongest prominent safety warning. It does not mean every patient will experience the complication, but it does mean the risk deserves careful screening and monitoring.

Serious infections

Infliximab can reduce the body’s ability to fight bacteria, viruses, fungi, and other pathogens. Reported infections include tuberculosis, bacterial sepsis, histoplasmosis, coccidioidomycosis, candidiasis, pneumocystosis, listeriosis, and other opportunistic infections.

Call a healthcare professional promptly for fever, shaking chills, persistent cough, shortness of breath, night sweats, unexplained weight loss, severe fatigue, painful skin, an open sore, diarrhea, abdominal pain, or other possible signs of infection.

Remicade should not be started during an active serious infection. Treatment may need to be held if a significant infection develops.

Tuberculosis and hepatitis B reactivation

Patients are screened for latent or active tuberculosis before treatment and may be retested during therapy. A negative initial test does not eliminate every future risk.

Hepatitis B screening is also important because infliximab can reactivate a previous infection. Symptoms such as yellow skin or eyes, dark urine, pale stools, nausea, poor appetite, severe fatigue, or right-sided abdominal pain require medical attention.

Cancer risk

Lymphoma and other malignancies have been reported in patients taking TNF blockers. A rare, aggressive cancer called hepatosplenic T-cell lymphoma has occurred mainly in adolescent and young adult males with Crohn’s disease or ulcerative colitis who were also using azathioprine or 6-mercaptopurine.

The absolute risk for an individual may remain low, and uncontrolled inflammatory disease carries risks of its own. The decision should be based on age, diagnosis, previous cancer history, combination therapy, disease severity, and available alternatives.

Other potentially serious complications

• Heart failure: New or worsening heart failure can occur. Report swelling, sudden weight gain, increasing breathlessness, or difficulty lying flat.
• Liver injury: Rare cases of severe liver damage and autoimmune hepatitis have been reported.
• Blood-cell abnormalities: Low white cells, platelets, or other blood cells may cause persistent fever, unusual bruising, bleeding, or marked weakness.
• Neurologic disorders: TNF blockers have been linked to new or worsening demyelinating conditions, seizures, optic neuritis, and related problems.
• Lupus-like syndrome: Symptoms may include rash, joint pain, chest discomfort, and unusual sensitivity to sunlight.
• Cardiovascular or cerebrovascular reactions: Heart attack, stroke, abnormal heart rhythm, and significant blood-pressure changes have been reported during or shortly after infusion.
• Severe skin reactions: Blistering, peeling, painful sores, or a widespread rash requires urgent assessment.

Emergency help is appropriate for severe breathing difficulty, throat swelling, chest pain, fainting, sudden weakness, speech difficulty, vision loss, a seizure, or a rapidly spreading blistering rash.

Tests and precautions before starting Remicade

Before the first infusion, the care team will review medical history, current prescriptions, previous biologic treatment, infection exposure, vaccination status, and pregnancy considerations.

Common pre-treatment steps may include:

• Tuberculosis screening
• Hepatitis B testing
• Blood-cell counts
• Liver-function testing
• Review of current or recurrent infections
• Review of heart failure or cardiovascular disease
• Review of multiple sclerosis, optic neuritis, seizures, or other neurologic conditions
• Review of previous cancer or cancer risk factors
• Updating appropriate vaccinations before immunosuppression begins

Monitoring during treatment may include blood tests, infection screening, skin examinations, disease-specific testing, and assessment for loss of response.

Drug interactions, vaccines, pregnancy, and breastfeeding

Other immune-suppressing medications

Using multiple biologic immune therapies together can substantially increase infection risk without necessarily improving results. Remicade is generally not combined with biologic drugs such as abatacept, anakinra, or tocilizumab.

Methotrexate is intentionally combined with Remicade for rheumatoid arthritis and may be used in selected patients with other conditions. The decision involves balancing effectiveness, antibody formation, infection risk, and other adverse effects.

Patients should provide a complete list of prescriptions, over-the-counter drugs, vitamins, and supplements. Starting or stopping infliximab may affect how the body handles certain narrow-therapeutic-index medicines, so additional monitoring may sometimes be needed.

Vaccines

Live vaccines should generally be avoided during Remicade treatment. Examples may include certain formulations of measles-mumps-rubella, chickenpox, yellow fever, and intranasal influenza vaccines.

Many non-live vaccines can be given, but timing should be discussed with the prescribing team. Adults and children should ideally receive age-appropriate immunizations before treatment begins.

For infants exposed to infliximab during pregnancy, the FDA labeling recommends waiting at least six months after birth before administering live vaccines. The pediatrician should always be told about pregnancy exposure.

Pregnancy and breastfeeding

Pregnancy planning should involve the treating specialist and obstetric team. Available evidence has not shown a clear association between infliximab and major pregnancy complications, while an uncontrolled autoimmune disease can itself create serious risks.

Infliximab can cross the placenta, especially later in pregnancy. Treatment timing may therefore be individualized. Current rheumatology guidance generally considers breastfeeding compatible with infliximab, but each patient’s circumstances should still be reviewed.

How much does Remicade cost?

The cost of Remicade in the United States can be substantial, and there is no single meaningful price that applies to everyone. The sticker price may run into thousands of dollars for one treatment, but the patient’s actual responsibility can be dramatically different.

Factors that influence the total bill

• The patient’s weight and prescribed mg/kg dose
• The number of 100-mg vials required
• Brand-name Remicade versus an infliximab biosimilar
• Hospital outpatient department versus independent infusion center
• Infusion administration and facility fees
• Laboratory tests and office visits
• Premedications and medical supplies
• Insurance deductible, coinsurance, network, and prior-authorization rules
• Manufacturer assistance or independent foundation support

Remicade is often covered as a medical benefit rather than a traditional pharmacy benefit because it is administered by a healthcare professional. Medicare commonly handles qualifying outpatient infusions under Part B, while commercial plans have their own medical-benefit rules.

Ways to reduce out-of-pocket expenses

At the time of writing, the manufacturer advertises a savings program under which eligible patients with commercial or private insurance may pay as little as $5 per infusion. Annual maximums, eligibility rules, and other restrictions apply. The program does not cover the cost of administering the infusion and is not available when Medicare, Medicaid, or another government program pays for treatment.

Patients can also ask about:

• Insurance benefit verification before the first dose
• A written estimate from the infusion facility
• Lower-cost in-network infusion locations
• FDA-approved infliximab biosimilars
• Manufacturer patient-support services
• Independent charitable foundations
• Hospital financial-assistance programs
• Appealing an insurance denial with the prescribing specialist

Always request estimates for both the medication and the administration charge. The drug may be approved while the facility fee quietly waits behind a curtain wearing a fake mustache.

Remicade biosimilars

A biosimilar is a biologic product that is highly similar to an already approved reference drug and has no clinically meaningful differences in safety, purity, or effectiveness. It is not an ordinary generic because biologics are large, complex proteins that cannot be copied molecule for molecule in the same way as a simple tablet.

FDA-approved infliximab biosimilars used in the United States include products such as Inflectra, Renflexis, and Avsola. They generally follow the same condition-specific dosing approach as the reference infliximab product.

An insurer or healthcare system may prefer a biosimilar because of contracted pricing. A switch does not automatically mean the medication is inferior. Patients should still confirm the exact product name, infusion schedule, authorization status, and out-of-pocket cost.

Practical experiences: what treatment may feel like in real life

The following examples are composite treatment experiences, not promises of results or accounts from one identifiable patient.

The first infusion can feel longer than it is

A first-time patient may arrive early, sign several forms, answer questions about infections, and have vital signs checked before the medication is prepared. Since the dose is weight-based and the infusion is mixed for the individual, the process may not begin the instant the patient sits down.

Once the IV is placed, the actual infusion usually lasts at least two hours. Add preparation and observation, and the visit can occupy a meaningful part of the day. A phone charger, headphones, water, a light snack, and a sweater can become surprisingly important equipment. Infusion centers are frequently chilly, apparently because blankets enjoy job security.

Some people feel perfectly normal afterward. Others experience tiredness, a mild headache, or a “washed out” sensation for the rest of the day. Planning a low-demand evening after the first few infusions can be sensible until the individual response becomes predictable.

The induction schedule makes the calendar part of treatment

The dose at week zero is followed by treatment at weeks two and six. That early schedule can feel busy, but maintenance infusions are usually more widely spaced. Patients often set several reminders because missing an infusion is much easier when daily life becomes hectic and symptoms are finally improving.

Travel may require extra planning. Patients can ask how much flexibility exists around the scheduled date, whether another approved infusion location can be used, and how insurance authorization would work. Rearranging treatment without the medical office can create coverage problems or an unintended interruption.

Improvement may be gradual rather than cinematic

One patient may notice less abdominal urgency after two doses. Another may realize after several months that morning stiffness no longer lasts until lunch. The change may not arrive with inspirational music and a dramatic sunrise. It may appear as fewer nighttime bathroom trips, enough energy to cook dinner, or the ability to button a shirt without wincing.

Keeping a brief symptom record can reveal progress that is otherwise easy to miss. Useful details include pain, bowel frequency, bleeding, fatigue, skin changes, mobility, sleep, and steroid use. The record also helps identify whether symptoms reliably return before the next infusion.

Side-effect tracking helps separate patterns from coincidence

A headache after one infusion may be random. A similar headache after four consecutive treatments is a pattern worth discussing. Patients may record when a symptom began, how long it lasted, what medications were given beforehand, and whether the infusion rate changed.

Possible infection symptoms should not be treated as ordinary inconveniences. A patient who develops fever, a persistent cough, painful urination, a spreading skin infection, or severe diarrhea should contact the medical team rather than waiting for infusion day. The office may postpone treatment until the infection is assessed or treated.

Insurance can become the least charming member of the care team

Some patients are approved for Remicade and later receive notice that the plan prefers a biosimilar. Others discover that the same medication costs far more at a hospital-based center than at an independent facility. Asking for benefit verification, prior-authorization confirmation, and a written estimate before each new coverage year can prevent unpleasant surprises.

A biosimilar switch may feel unsettling, especially after a patient has finally found a successful therapy. Discussing concerns with the specialist is appropriate. The key questions include whether the dose and interval remain unchanged, how response will be monitored, and whom to contact if symptoms or infusion reactions appear.

When the benefit seems to fade

Some patients initially respond and later notice symptoms returning earlier in the infusion cycle. This does not automatically mean the drug has permanently failed. The clinician may evaluate disease activity, look for infection or another explanation, and sometimes measure infliximab levels or antibodies against the medication.

Depending on the findings and diagnosis, options may include adjusting the dose, changing the interval, adding or modifying another medicine, or switching therapies. Those decisions require specialist supervision because simply increasing immune suppression can raise serious risks.

For many people, Remicade treatment eventually settles into a routine: check in, confirm there is no infection, start the IV, read or nap, schedule the next visit, and return to ordinary life. The most successful experience usually involves more than the medication itself. Clear communication, consistent monitoring, reliable scheduling, vaccination planning, cost preparation, and prompt reporting of new symptoms all help make treatment safer and more manageable.

Final takeaway

Remicade can be an effective treatment for Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and severe plaque psoriasis. Its benefits can include symptom control, improved function, reduced tissue damage, mucosal healing, and sustained remission.

Those potential benefits come with meaningful responsibilities. Patients need infection screening, condition-specific dosing, regular infusions, ongoing monitoring, vaccine planning, and a clear understanding of urgent warning signs. Cost should also be discussed before treatment begins, including the drug, infusion services, insurance requirements, assistance programs, and biosimilar options.

Remicade is neither a miracle potion nor a villain in a tiny glass vial. It is a serious medical tool whose value depends on selecting the right patient, using the right dose, and keeping the healthcare team informed.